- Axplora is investing €6.5 million to expand its API manufacturing site in Vizag, India, supporting global demand and supply chain resilience.
- Both Vizag and Chennai sites completed USFDA inspections in 2025 with Voluntary Action Indicated (VAI) classifications.
Axplora, a global manufacturer of small-molecule active pharmaceutical ingredients (APIs), has announced a €6.5 million investment in its Vizag site in India. The expansion aims to increase production capacity, create new employment opportunities, and strengthen the company’s vertically integrated operations.
This development follows successful routine inspections by the US Food and Drug Administration (USFDA) at both Axplora’s Vizag and Chennai facilities in 2025. Each site received a Voluntary Action Indicated (VAI) classification, underscoring compliance with international regulatory standards and a focus on continuous improvement.
“This investment reflects Axplora’s strategic commitment to operational excellence and customer-centric growth,” said Martin Meeson, CEO of Axplora. He added that strengthening infrastructure in Vizag supports the delivery of reliable, high-quality solutions to customers globally.
The USFDA inspection at Chennai highlighted strong adherence to current Good Manufacturing Practices (cGMP), streamlined documentation, and high standards of facility maintenance. Anant Barbadikar, Co-President of PharmaZell and Chief Operating Officer in India, said the inspection outcomes demonstrate “our team’s diligence and our unwavering focus on quality.”
